Global Canine Flu Therapeutics

Canine Flu Therapeutics Comprehensive Study by Application (Vet Clinics, Veterinary Hospitals, Animal Healthcare Facilities), Treatment Type (Vaccines, Anti-inflammatory Drugs, Antibiotics, Others) Players and Region - Global Market Outlook to 2030

Canine Flu Therapeutics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Canine Flu Therapeutics
Canine influenza (CI), is also known as dog flu, is an extremely contagious viral infection affecting dogs and also cats. Influenza viruses belong to the family Orthomyxoviridae. Canine influenza is a Type A influenza virus and is further recognized based on the composition of two specific proteins in the lipid outer layer of the capsid that is hemagglutinin (HA) and neuraminidase (NA). At present, H3N8 and H3N2 are the two strains of canine influenza virus that have been identified in the United States. Nearly all dogs exposed to the canine influenza virus become infected, with approx. 80% of developing clinical signs of disease and nearly 20% of infected dogs that do not display any clinical signs of disease can still shed the virus and spread the infection.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Canine Flu Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck Animal Health (United States), GlaxoSmithKline (United Kingdom), Pfizer (United States), Zoetis (United States), Novartis (Switzerland), Sanofi (France), Boehringer Ingelheim International (Germany), Bristol-Myers Squibb (United States), Roche (Switzerland), Eli Lilly and Company (United States) and Abbott Laboratories (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Hoffmann La Roche Limited (Switzerland) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Canine Flu Therapeutics market by , Application (Vet Clinics, Veterinary Hospitals and Animal Healthcare Facilities) and Region.



On the basis of geography, the market of Canine Flu Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Vaccines will boost the Canine Flu Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Lower Cost of Procedure As Compared To Conventional Methods

Market Growth Drivers:
The Growing Number of Incidences of Canine Influenza Mainly in North America and Increasing Awareness of Conducted Canine Influenza

Challenges:
Limited Number of Vaccines Available In the Market

Restraints:
High cost of therapeutics.

Opportunities:
The Rise in FDA and Research Institutes’ Approvals for Canine Influenza Treatment

Market Leaders and their expansionary development strategies
In November 2023, From coast to coast, including states as close as Illinois, hundreds of dogs are falling ill with an unknown respiratory illness experts say starts as a cough but doesn't respond to regular antibiotics.
In December 2023, A mystery respiratory illness has stricken dogs in at least 14 states, according to the American Veterinary Medical Association, which is asking vets to report cases while laboratories race to isolate the pathogen. Researchers are still attempting to determine if the disease, which can be fatal, is viral or bacterial, and whether it could be a variant of the well-understood canine disease known as "kennel cough," the association said.


Key Target Audience
Canine Flu Therapeutics Service Providers, Pharmaceutical Industry, End-Users, Regulatory Bodies, Governmental Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Vet Clinics
  • Veterinary Hospitals
  • Animal Healthcare Facilities
By Treatment Type
  • Vaccines
  • Anti-inflammatory Drugs
  • Antibiotics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Number of Incidences of Canine Influenza Mainly in North America
      • 3.2.2. Increasing Awareness of Conducted Canine Influenza
    • 3.3. Market Challenges
      • 3.3.1. Limited Number of Vaccines Available In the Market
    • 3.4. Market Trends
      • 3.4.1. Lower Cost of Procedure As Compared To Conventional Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Canine Flu Therapeutics, by Application, Treatment Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Canine Flu Therapeutics (Value)
      • 5.2.1. Global Canine Flu Therapeutics by: Application (Value)
        • 5.2.1.1. Vet Clinics
        • 5.2.1.2. Veterinary Hospitals
        • 5.2.1.3. Animal Healthcare Facilities
      • 5.2.2. Global Canine Flu Therapeutics by: Treatment Type (Value)
        • 5.2.2.1. Vaccines
        • 5.2.2.2. Anti-inflammatory Drugs
        • 5.2.2.3. Antibiotics
        • 5.2.2.4. Others
      • 5.2.3. Global Canine Flu Therapeutics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Canine Flu Therapeutics (Price)
  • 6. Canine Flu Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck Animal Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Zoetis (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim International (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Abbott Laboratories (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Canine Flu Therapeutics Sale, by Application, Treatment Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Canine Flu Therapeutics (Value)
      • 7.2.1. Global Canine Flu Therapeutics by: Application (Value)
        • 7.2.1.1. Vet Clinics
        • 7.2.1.2. Veterinary Hospitals
        • 7.2.1.3. Animal Healthcare Facilities
      • 7.2.2. Global Canine Flu Therapeutics by: Treatment Type (Value)
        • 7.2.2.1. Vaccines
        • 7.2.2.2. Anti-inflammatory Drugs
        • 7.2.2.3. Antibiotics
        • 7.2.2.4. Others
      • 7.2.3. Global Canine Flu Therapeutics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Canine Flu Therapeutics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Canine Flu Therapeutics: by Application(USD Million)
  • Table 2. Canine Flu Therapeutics Vet Clinics , by Region USD Million (2018-2023)
  • Table 3. Canine Flu Therapeutics Veterinary Hospitals , by Region USD Million (2018-2023)
  • Table 4. Canine Flu Therapeutics Animal Healthcare Facilities , by Region USD Million (2018-2023)
  • Table 5. Canine Flu Therapeutics: by Treatment Type(USD Million)
  • Table 6. Canine Flu Therapeutics Vaccines , by Region USD Million (2018-2023)
  • Table 7. Canine Flu Therapeutics Anti-inflammatory Drugs , by Region USD Million (2018-2023)
  • Table 8. Canine Flu Therapeutics Antibiotics , by Region USD Million (2018-2023)
  • Table 9. Canine Flu Therapeutics Others , by Region USD Million (2018-2023)
  • Table 10. South America Canine Flu Therapeutics, by Country USD Million (2018-2023)
  • Table 11. South America Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 12. South America Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 13. Brazil Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 14. Brazil Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 15. Argentina Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 16. Argentina Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 17. Rest of South America Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 18. Rest of South America Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 19. Asia Pacific Canine Flu Therapeutics, by Country USD Million (2018-2023)
  • Table 20. Asia Pacific Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 21. Asia Pacific Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 22. China Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 23. China Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 24. Japan Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 25. Japan Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 26. India Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 27. India Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 28. South Korea Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 29. South Korea Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 30. Taiwan Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 31. Taiwan Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 32. Australia Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 33. Australia Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 36. Europe Canine Flu Therapeutics, by Country USD Million (2018-2023)
  • Table 37. Europe Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 38. Europe Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 39. Germany Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 40. Germany Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 41. France Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 42. France Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 43. Italy Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 44. Italy Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 45. United Kingdom Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 46. United Kingdom Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 47. Netherlands Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 48. Netherlands Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 49. Rest of Europe Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 50. Rest of Europe Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 51. MEA Canine Flu Therapeutics, by Country USD Million (2018-2023)
  • Table 52. MEA Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 53. MEA Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 54. Middle East Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 55. Middle East Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 56. Africa Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 57. Africa Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 58. North America Canine Flu Therapeutics, by Country USD Million (2018-2023)
  • Table 59. North America Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 60. North America Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 61. United States Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 62. United States Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 63. Canada Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 64. Canada Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 65. Mexico Canine Flu Therapeutics, by Application USD Million (2018-2023)
  • Table 66. Mexico Canine Flu Therapeutics, by Treatment Type USD Million (2018-2023)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Canine Flu Therapeutics: by Application(USD Million)
  • Table 79. Canine Flu Therapeutics Vet Clinics , by Region USD Million (2025-2030)
  • Table 80. Canine Flu Therapeutics Veterinary Hospitals , by Region USD Million (2025-2030)
  • Table 81. Canine Flu Therapeutics Animal Healthcare Facilities , by Region USD Million (2025-2030)
  • Table 82. Canine Flu Therapeutics: by Treatment Type(USD Million)
  • Table 83. Canine Flu Therapeutics Vaccines , by Region USD Million (2025-2030)
  • Table 84. Canine Flu Therapeutics Anti-inflammatory Drugs , by Region USD Million (2025-2030)
  • Table 85. Canine Flu Therapeutics Antibiotics , by Region USD Million (2025-2030)
  • Table 86. Canine Flu Therapeutics Others , by Region USD Million (2025-2030)
  • Table 87. South America Canine Flu Therapeutics, by Country USD Million (2025-2030)
  • Table 88. South America Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 89. South America Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 90. Brazil Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 91. Brazil Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 92. Argentina Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 93. Argentina Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 94. Rest of South America Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 95. Rest of South America Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 96. Asia Pacific Canine Flu Therapeutics, by Country USD Million (2025-2030)
  • Table 97. Asia Pacific Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 98. Asia Pacific Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 99. China Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 100. China Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 101. Japan Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 102. Japan Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 103. India Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 104. India Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 105. South Korea Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 106. South Korea Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 107. Taiwan Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 108. Taiwan Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 109. Australia Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 110. Australia Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 111. Rest of Asia-Pacific Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 112. Rest of Asia-Pacific Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 113. Europe Canine Flu Therapeutics, by Country USD Million (2025-2030)
  • Table 114. Europe Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 115. Europe Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 116. Germany Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 117. Germany Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 118. France Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 119. France Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 120. Italy Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 121. Italy Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 122. United Kingdom Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 123. United Kingdom Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 124. Netherlands Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 125. Netherlands Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 126. Rest of Europe Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 127. Rest of Europe Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 128. MEA Canine Flu Therapeutics, by Country USD Million (2025-2030)
  • Table 129. MEA Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 130. MEA Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 131. Middle East Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 132. Middle East Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 133. Africa Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 134. Africa Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 135. North America Canine Flu Therapeutics, by Country USD Million (2025-2030)
  • Table 136. North America Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 137. North America Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 138. United States Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 139. United States Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 140. Canada Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 141. Canada Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 142. Mexico Canine Flu Therapeutics, by Application USD Million (2025-2030)
  • Table 143. Mexico Canine Flu Therapeutics, by Treatment Type USD Million (2025-2030)
  • Table 144. Research Programs/Design for This Report
  • Table 145. Key Data Information from Secondary Sources
  • Table 146. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Canine Flu Therapeutics: by Application USD Million (2018-2023)
  • Figure 5. Global Canine Flu Therapeutics: by Treatment Type USD Million (2018-2023)
  • Figure 6. South America Canine Flu Therapeutics Share (%), by Country
  • Figure 7. Asia Pacific Canine Flu Therapeutics Share (%), by Country
  • Figure 8. Europe Canine Flu Therapeutics Share (%), by Country
  • Figure 9. MEA Canine Flu Therapeutics Share (%), by Country
  • Figure 10. North America Canine Flu Therapeutics Share (%), by Country
  • Figure 11. Global Canine Flu Therapeutics share by Players 2023 (%)
  • Figure 12. Global Canine Flu Therapeutics share by Players (Top 3) 2023(%)
  • Figure 13. Global Canine Flu Therapeutics share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Merck Animal Health (United States) Revenue, Net Income and Gross profit
  • Figure 16. Merck Animal Health (United States) Revenue: by Geography 2023
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer (United States) Revenue: by Geography 2023
  • Figure 21. Zoetis (United States) Revenue, Net Income and Gross profit
  • Figure 22. Zoetis (United States) Revenue: by Geography 2023
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 25. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi (France) Revenue: by Geography 2023
  • Figure 27. Boehringer Ingelheim International (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim International (Germany) Revenue: by Geography 2023
  • Figure 29. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 31. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 35. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 37. Global Canine Flu Therapeutics: by Application USD Million (2025-2030)
  • Figure 38. Global Canine Flu Therapeutics: by Treatment Type USD Million (2025-2030)
  • Figure 39. South America Canine Flu Therapeutics Share (%), by Country
  • Figure 40. Asia Pacific Canine Flu Therapeutics Share (%), by Country
  • Figure 41. Europe Canine Flu Therapeutics Share (%), by Country
  • Figure 42. MEA Canine Flu Therapeutics Share (%), by Country
  • Figure 43. North America Canine Flu Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck Animal Health (United States)
  • GlaxoSmithKline (United Kingdom)
  • Pfizer (United States)
  • Zoetis (United States)
  • Novartis (Switzerland)
  • Sanofi (France)
  • Boehringer Ingelheim International (Germany)
  • Bristol-Myers Squibb (United States)
  • Roche (Switzerland)
  • Eli Lilly and Company (United States)
  • Abbott Laboratories (United States)
Additional players considered in the study are as follows:
Hoffmann La Roche Limited (Switzerland) , Others
Select User Access Type

Key Highlights of Report


Jan 2024 231 Pages 64 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Canine Flu Therapeutics Quantitative research analysis
Global Canine Flu Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck Animal Health (United States), GlaxoSmithKline (United Kingdom), Pfizer (United States), Zoetis (United States), Novartis (Switzerland), Sanofi (France), Boehringer Ingelheim International (Germany), Bristol-Myers Squibb (United States), Roche (Switzerland), Eli Lilly and Company (United States) and Abbott Laboratories (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Lower Cost of Procedure As Compared To Conventional Methods" is seen as one of major influencing trends for Canine Flu Therapeutics Market during projected period 2023-2030.
The Canine Flu Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Canine Flu Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Microbubbles/Ultrasound Contrast Agents Comprehensive Study by Type (Cardiovascular Diseases, Renal Diseases, Others), Application (Molecular Imaging, Gene Therapy, Drug Delivery, Stem Cells Delivery...
$ 3500
Hepatitis Test Solution Comprehensive Study by Disease Type (Hepatitis B, Hepatitis C, Others), Technology (ELISA, Rapid Diagnostics Test, PCR, INAAT, Others), End User (Hospitals & Diagnostics Labs,...
$ 3450
Behcets Disease Comprehensive Study by Application (Men, Women, Others), Affected body part (Mouth, Skin, Genitals, Eyes, Joints, Blood Vessels, Digestive System, Brain), Treatment (Corticosteroids ...
$ 3750
Montelukast Intermediate Comprehensive Study by Application (Asthma, Allergic rhinitis, Bronchospasm, Urticaria) Players and Region - Global Market Outlook to 2030
$ 3500
Oral Thrush Comprehensive Study by Type (Pseudomembranous, Erythematous, Hyperplastic, Others), Application (Hospitals, Clinics), Diagnosis Methods (Examination, Biopsy, Endoscopy, Others.), Treatmen...
$ 3450
Treatment for Communicable Diseases Comprehensive Study by Type (Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others), Vaccines), Application (Hospital, Clinic, Other), Diseases...
$ 3750